Trial Profile
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Vaccines
- 27 Jul 2018 Results from NCT02140762 and its extension NCT02285777 studies published in the Vaccine
- 30 Oct 2016 Results assessing efficacy presented at the IDWeek 2016
- 18 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.